{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T09:24:53Z","timestamp":1790760293726,"version":"4.1.0"},"reference-count":29,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2020,10,7]],"date-time":"2020-10-07T00:00:00Z","timestamp":1602028800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cells"],"abstract":"<jats:p>Non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) are emerging worldwide epidemics, projected to become the leading cause of liver transplants. The strongest genetic risk factor for NAFLD\/NASH susceptibility and progression is a single-nucleotide polymorphism (SNP) in the patatin-like phospholipase domain-containing 3 gene (PNPLA3), rs738409, encoding the missense mutation I148M. This aminoacidic substitution interferes with the normal remodeling of lipid droplets in hepatocytes. It is also thought to play a key role in promoting liver fibrosis by inhibiting the release of retinol from hepatic stellate cells. Reducing PNPLA3 levels in individuals homozygous for 148M may be an effective treatment for the entire spectrum of NAFLD, based on gene dosage analysis in the human population, as well as the protective effect of another naturally occurring SNP (rs2294918) in PNPLA3 which, when co-inherited, reduces PNPLA3 mRNA levels to 50% and counteracts disease risk. By screening a clinical compound library targeting specific signaling pathways active in primary human hepatocytes, we identified momelotinib, a drug evaluated in clinical trials to treat myelofibrosis, as a potent down-regulator of PNPLA3 expression, across all genotypes. We found that momelotinib treatment yielded &gt;80% reduction in PNPLA3 mRNA in human primary hepatocytes and stellate cells, as well as in vivo via acute and chronic treatment of WT mice. Using a human multilineage 3D spheroid model of NASH homozygous for the PNPLA3 mutant protein, we additionally show that it decreases PNPLA3 mRNA as well as intracellular lipid content. Furthermore, we show that the effects on PNPLA3 coincide with changes in chromatin accessibility within regulatory regions of the PNPLA3 locus, consistent with inhibition occurring at the level of transcription. In addition to its primary reported targets, the JAK kinases, momelotinib inhibits several non-JAK kinases, including ACVR1. Using a combination of targeted siRNA knockdowns and signaling pathway perturbations, we show that momelotinib reduces the expression of the PNPLA3 gene largely through the inhibition of BMP signaling rather than the JAK\/STAT pathway. Overall, our work identified momelotinib as a potential NASH therapeutic and uncovered previously unrecognized connections between signaling pathways and PNPLA3. These pathways may be exploited by drug modalities to \u201ctune down\u201d the level of gene expression, and therefore offer a potential therapeutic benefit to a high at-risk subset of NAFLD\/NASH patients.<\/jats:p>","DOI":"10.3390\/cells9102247","type":"journal-article","created":{"date-parts":[[2020,10,7]],"date-time":"2020-10-07T09:12:58Z","timestamp":1602061978000},"page":"2247","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":38,"title":["Discovery and Targeting of the Signaling Controls of PNPLA3 to Effectively Reduce Transcription, Expression, and Function in Pre-Clinical NAFLD\/NASH Settings"],"prefix":"10.3390","volume":"9","author":[{"given":"Brian E.","family":"Schwartz","sequence":"first","affiliation":[{"name":"CAMP4 Therapeutics, Cambridge, MA 02139, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vaishnavi","family":"Rajagopal","sequence":"additional","affiliation":[{"name":"CAMP4 Therapeutics, Cambridge, MA 02139, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia","family":"Smith","sequence":"additional","affiliation":[{"name":"CAMP4 Therapeutics, Cambridge, MA 02139, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0824-9148","authenticated-orcid":false,"given":"Evan","family":"Cohick","sequence":"additional","affiliation":[{"name":"CAMP4 Therapeutics, Cambridge, MA 02139, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gavin","family":"Whissell","sequence":"additional","affiliation":[{"name":"CAMP4 Therapeutics, Cambridge, MA 02139, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Gamboa","sequence":"additional","affiliation":[{"name":"CAMP4 Therapeutics, Cambridge, MA 02139, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rutuja","family":"Pai","sequence":"additional","affiliation":[{"name":"CAMP4 Therapeutics, Cambridge, MA 02139, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alla","family":"Sigova","sequence":"additional","affiliation":[{"name":"CAMP4 Therapeutics, Cambridge, MA 02139, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3912-7458","authenticated-orcid":false,"given":"Iris","family":"Grossman","sequence":"additional","affiliation":[{"name":"CAMP4 Therapeutics, Cambridge, MA 02139, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Bumcrot","sequence":"additional","affiliation":[{"name":"CAMP4 Therapeutics, Cambridge, MA 02139, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kavitha","family":"Sasidharan","sequence":"additional","affiliation":[{"name":"Department of Molecular and Clinical Medicine, University of Gothenburg, SE-413 45 Gothenburg, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Romeo","sequence":"additional","affiliation":[{"name":"Department of Molecular and Clinical Medicine, University of Gothenburg, SE-413 45 Gothenburg, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfica","family":"Sehgal","sequence":"additional","affiliation":[{"name":"CAMP4 Therapeutics, Cambridge, MA 02139, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2478-225X","authenticated-orcid":false,"given":"Piero","family":"Pingitore","sequence":"additional","affiliation":[{"name":"Department of Molecular and Clinical Medicine, University of Gothenburg, SE-413 45 Gothenburg, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2020,10,7]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Jakobsdottir, J., Gorin, M.B., Conley, Y.P., Ferrell, R.E., and Weeks, D.E. (2009). Interpretation of genetic association studies: Markers with replicated highly significant odds ratios may be poor classifiers. PLoS Genet., 5.","DOI":"10.1371\/journal.pgen.1000337"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1038\/nrg3523","article-title":"Bringing genome-wide association findings into clinical use","volume":"14","author":"Manolio","year":"2013","journal-title":"Nat. Rev. Genet."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1038\/ng.257","article-title":"Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease","volume":"40","author":"Romeo","year":"2008","journal-title":"Nat. Genet."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"33336","DOI":"10.1074\/jbc.M105193200","article-title":"Adiponutrin, a transmembrane protein corresponding to a novel dietary- and obesity-linked mRNA specifically expressed in the adipose lineage","volume":"276","author":"Baulande","year":"2001","journal-title":"J. Biol. Chem."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.cmet.2019.12.002","article-title":"Leveraging human genetics to identify potential new treatments for fatty liver disease","volume":"31","author":"Romeo","year":"2020","journal-title":"Cell Metab."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.jhep.2014.02.030","article-title":"Carriage of the PNPLA3 rs738409 C > G polymorphism confers an increased risk of non-alcoholic fatty liver disease associated hepatocellular carcinoma","volume":"61","author":"Liu","year":"2014","journal-title":"J. Hepatol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"37085","DOI":"10.1074\/jbc.M111.290114","article-title":"Expression and characterization of a PNPLA3 protein isoform (I148M) associated with nonalcoholic fatty liver disease","volume":"286","author":"Huang","year":"2011","journal-title":"J. Biol. Chem."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"9521","DOI":"10.1073\/pnas.1901974116","article-title":"Accumulation of PNPLA3 on lipid droplets is the basis of associated hepatic steatosis","volume":"116","author":"BasuRay","year":"2019","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1002\/hep.30583","article-title":"PNPLA3, CGI-58, and inhibition of hepatic triglyceride hydrolysis in mice","volume":"69","author":"Wang","year":"2019","journal-title":"Hepatology"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"4077","DOI":"10.1093\/hmg\/ddu121","article-title":"PNPLA3 has retinyl-palmitate lipase activity in human hepatic stellate cells","volume":"23","author":"Pirazzi","year":"2014","journal-title":"Hum. Mol. Genet."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1002\/hep.29041","article-title":"The PNPLA3 I148M variant modulates the fibrogenic phenotype of human hepatic stellate cells","volume":"65","author":"Bruschi","year":"2017","journal-title":"Hepatology"},{"key":"ref_12","first-page":"5212","article-title":"PNPLA3 overexpression results in reduction of proteins predisposing to fibrosis","volume":"25","author":"Pingitore","year":"2016","journal-title":"Hum. Mol. Genet."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.molmet.2019.01.013","article-title":"Pnpla3 silencing with antisense oligonucleotides ameliorates nonalcoholic steatohepatitis and fibrosis in Pnpla3 I148M knock-in mice","volume":"22","author":"Linden","year":"2019","journal-title":"Mol. Metab."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1038\/leu.2009.50","article-title":"CYT387, a selective JAK1\/JAK2 inhibitor: In vitro assessment of kinase selectivity and preclinical studies using cell lines and primary cells from polycythemia vera patients","volume":"23","author":"Pardanani","year":"2009","journal-title":"Leukemia"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"5232","DOI":"10.1182\/blood-2009-05-223727","article-title":"CYT387, a novel JAK2 inhibitor, induces hematologic responses and normalizes inflammatory cytokines in murine myeloproliferative neoplasms","volume":"115","author":"Tyner","year":"2010","journal-title":"Blood"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1182\/blood-2016-09-740092","article-title":"Momelotinib inhibits ACVR1\/ALK2, decreases hepcidin production, and ameliorates anemia of chronic disease in rodents","volume":"129","author":"Asshoff","year":"2017","journal-title":"Blood"},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Pingitore, P., Sasidharan, K., Ekstrand, M., Prill, S., Linden, D., and Romeo, S. (2019). Human multilineage 3D spheroids as a model of liver steatosis and fibrosis. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20071629"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1172\/JCI119892","article-title":"Immunoglobulin treatment reduces atherosclerosis in apo E knockout mice","volume":"102","author":"Nicoletti","year":"1998","journal-title":"J. Clin. Investig."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1038\/nprot.2006.98","article-title":"Chromatin immunoprecipitation and microarray-based analysis of protein location","volume":"1","author":"Lee","year":"2006","journal-title":"Nat. Protoc."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1038\/nmeth.4396","article-title":"An improved ATAC-seq protocol reduces background and enables interrogation of frozen tissues","volume":"14","author":"Corces","year":"2017","journal-title":"Nat. Methods"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/s10637-018-0650-5","article-title":"Phase 1 dose-escalation study of momelotinib, a Janus kinase 1\/2 inhibitor, combined with gemcitabine and nab-paclitaxel in patients with previously untreated metastatic pancreatic ductal adenocarcinoma","volume":"37","author":"Ng","year":"2019","journal-title":"Investig. New Drugs"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1002\/hep.26170","article-title":"Role of patatin-like phospholipase domain-containing 3 on lipid-induced hepatic steatosis and insulin resistance in rats","volume":"57","author":"Kumashiro","year":"2013","journal-title":"Hepatology"},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Nickel, J., and Mueller, T.D. (2019). Specification of BMP signaling. Cells, 8.","DOI":"10.3390\/cells8121579"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.1194\/jlr.P900013-JLR200","article-title":"A nonsynonymous gene variant in the adiponutrin gene is associated with nonalcoholic fatty liver disease severity","volume":"50","author":"Sookoian","year":"2009","journal-title":"J. Lipid Res."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1002\/hep.23622","article-title":"Homozygosity for the patatin-like phospholipase-3\/adiponutrin I148M polymorphism influences liver fibrosis in patients with nonalcoholic fatty liver disease","volume":"51","author":"Valenti","year":"2010","journal-title":"Hepatology"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1002\/hep.23768","article-title":"PNPLA3 variants specifically confer increased risk for histologic nonalcoholic fatty liver disease but not metabolic disease","volume":"52","author":"Speliotes","year":"2010","journal-title":"Hepatology"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1002\/hep.23759","article-title":"The association of genetic variability in patatin-like phospholipase domain-containing protein 3 (PNPLA3) with histological severity of nonalcoholic fatty liver disease","volume":"52","author":"Rotman","year":"2010","journal-title":"Hepatology"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1002\/hep.28370","article-title":"The rs2294918 E434K variant modulates patatin-like phospholipase domain-containing 3 expression and liver damage","volume":"63","author":"Donati","year":"2016","journal-title":"Hepatology"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1038\/nrg.2016.112","article-title":"Organization and function of the 3D genome","volume":"17","author":"Bonev","year":"2016","journal-title":"Nat. Rev. Genet."}],"container-title":["Cells"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4409\/9\/10\/2247\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T10:17:07Z","timestamp":1760177827000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4409\/9\/10\/2247"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,7]]},"references-count":29,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2020,10]]}},"alternative-id":["cells9102247"],"URL":"https:\/\/doi.org\/10.3390\/cells9102247","relation":{},"ISSN":["2073-4409"],"issn-type":[{"value":"2073-4409","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,7]]}}}